November 18th, 2024

Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment.  This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors. This study is mainly supported by the Asociación Española Contra el Cáncer (AECC) through AUSONIA and has also received funding from the Breast Cancer Research Foundation (BCRF), Fundación BBVA through the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), which is one of VHIO's Institutional Programs focused on developing new advanced therapies.

Read more sobre "Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors"

November 6th, 2024

Hospital del Mar to Coordinate a €10 Million Study to Develop Blood Stem Cells in the Laboratory

This study will be conducted in collaboration with the Josep Carreras Leukemia Research Institute, and researchers from Finland, the Netherlands, and the United Kingdom will participate. The goal is to develop and validate protocols and systems for generating laboratory-derived stem cells to regenerate patients' blood. The European Research Council, which provides these grants, is the leading funding organization for advanced and excellent research on the continent. It is an organization created by the European Union.

Read more sobre "Hospital del Mar to Coordinate a €10 Million Study to Develop Blood Stem Cells in the Laboratory"

September 20th, 2024

Intense physical exercise reduces levels of the worst part of bad cholesterol

The oxidation of low-density lipoproteins present in the blood (LDL) or bad cholesterol opens the door to an increased cardiovascular risk, as this oxidized cholesterol is more likely to deposit in the arteries, leading to the growth of cholesterol plaques that cause arteriosclerosis. Engaging in intense physical activity reduces the oxidation of LDL particles, lowering the risk of cardiovascular disease. Thirty minutes of intense exercise daily reduces oxidized LDL cholesterol by 8 to 10%. However, the effect is only seen in men. Low or moderate intensity exercises do not have the same effect. This is revealed by a study from the Hospital del Mar Research Institute and the Faculty of Medicine of the University of Vic-Central University of Catalonia, published in the Spanish Journal of Cardiology.

Read more sobre "Intense physical exercise reduces levels of the worst part of bad cholesterol"

Mar Sèniors celebra su segundo aniversario con el acto "Fer anys amb salut"

20 de novembre de 2024

Evolución de los Ensayos Clínicos: Nuevos Retos y Oportunidades Innovadoras

4 de diciembre de 2024

Mitos y realidades en la alimentación durante el cáncer

19 de diciembre del 2024